Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities). Q2 fiscal 2026 results for quarter ended June 30, 2026 announced.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026 announced
- Full financial results and management commentary available in Exhibit 99.1
- Investor focus: sequencing demand, revenue trajectory, cash usage and outlook in the attached release
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 40 employees, or 8% of staff
- Annualized operating expense savings targeted at $30 million to $40 million by end-2027
- Approximately $2.0 million in pre-tax severance and related charges expected in Q3 2026
- Restructuring signals near-term cost focus, with potential execution risk to business operations
Item 5.02 · Departure/Election of Directors or Officers
- Mark Van Oene becomes CEO and director August 5, succeeding Christian Henry, who remains on the Board
- CEO compensation: $743,000 salary, 100% target bonus, $1.6875M option, and $562,500 RSU award
- Change-in-control severance expanded to 18 months’ salary and COBRA coverage from 12 months
- Henry receives $1,161,685.50 separation payment, salary through December 31, and continued equity vesting
- Leadership transition creates near-term cash and equity costs while preserving Henry’s Board involvement
Item 7.01 · Regulation FD Disclosure
- August 5, 2026 press release announces leadership changes described under Item 5.02
- Leadership transition may affect PACB’s strategic execution and investor assessment of management continuity
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $39.0M, down from $39.8M; consumables rose to $20.1M while instrument revenue declined to $12.8M
- Revio placements increased to 20 from 15, but Vega placements fell to 26 from 38 and annualized Revio pull-through declined to ~$202,000
- Non-GAAP gross margin fell to 36% from 38%, pressured by compute and memory costs, Vega transition costs, and lower Revio pricing
- Cash and investments declined to $236.9M from $314.7M at year-end, highlighting funding risk amid a $44.7M GAAP quarterly net loss
- 2026 revenue guidance remains $155M-$165M, with SPRQ-Nx rollout and Basecamp Research execution key commercialization catalysts
Item EX-99.2 · Exhibit EX-99.2
- Mark Van Oene appointed President and CEO effective August 5, 2026, succeeding Christian Henry after six years
- Internal succession: Van Oene previously served as COO since 2021, reducing near-term leadership disruption risk
- Henry remains on PacBio’s Board and serves as business advisor through at least year-end 2026, supporting transition continuity
- Strategic emphasis shifts toward clinical and diagnostics markets, AI-enabled sequencing products, and clinically relevant databases
- Van Oene also joins the Board, aligning executive leadership and board oversight during PacBio’s next growth phase
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K filings
Get the next PACB 8-K as it lands
Follow PACB for push alerts, or ask the research agent what this filing means.